For the quarter ending 2025-09-30, NEPH had $97K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total net revenues | 14,060 | - |
| Cost of goods sold | 5,196 | - |
| Gross margin | 8,864 | - |
| Research and development | 944 | - |
| Selling, general and administrative | 6,684 | - |
| Other operating expenses | 108 | - |
| Total operating expenses | 7,736 | - |
| Operating income (loss) | 1,128 | - |
| Total other expense (income), net | 16 | - |
| Income (loss) before income taxes | 1,144 | - |
| Income tax expense | 12 | - |
| Net income (loss) | 337 | 795 |
| Depreciation of property and equipment | 12 | 30 |
| Amortization of intangible assets, license and supply agreement and finance lease right-of-use asset | 22 | 43 |
| Stock-based compensation | 70 | 147 |
| Gain on disposal of equipment | - | 0 |
| Inventory impairments and write offs | 15 | 41 |
| Loss (gain) on foreign currency transactions | 8 | -7 |
| Accounts receivable | 621 | 259 |
| Inventory | 516 | -337 |
| Prepaid expenses and other current assets | -91 | 85 |
| Right-of-use assets | -90 | -175 |
| Accounts payable | 312 | -24 |
| Other assets | - | 0 |
| Accrued expenses | 380 | 277 |
| Lease liabilities | -85 | -168 |
| Net cash provided by (used in) operating activities | 99 | 1,316 |
| Proceeds from sale of equipment | - | 0 |
| Purchase of property and equipment | - | 0 |
| Net cash used in investing activities | - | 0 |
| Principal payments on finance lease liability | 2 | 2 |
| Net cash used in financing activities | -2 | -2 |
| Net increase (decrease) in cash and cash equivalents | 97 | 1,314 |
| Cash and cash equivalents at beginning of period | 3,760 | - |
| Cash and cash equivalents at end of period | 5,171 | - |
NEPHROS INC (NEPH)
NEPHROS INC (NEPH)